Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

Users discussed increasing oral minoxidil from 2.5mg to 5mg for hair regrowth, with some considering higher doses despite potential side effects. They also mentioned using 1mg oral finasteride alongside minoxidil.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The user is considering switching from a topical minoxidil and finasteride solution to oral minoxidil to improve hair growth, while maintaining oral finasteride. They are concerned about potential shedding and whether they can maintain any new growth.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

_the_orange_box_'s experience using oral minoxidil, with discussion about finasteride and the potential side effects of both treatments. Other users shared their own experiences related to hair loss treatments.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Formula 82M, a minoxidil and retinol liquid, improved hair texture and filled in temples with baby hairs for the user, but its high cost and lack of reviews cause concern. Another user mentioned using a similar product, 82F, which has become less effective and expensive over time.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

User shared a 2-year progress update on hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily. They switched from topical to oral minoxidil for ease of use and showed significant improvement.

A 26-year-old male with grade 3 hair loss is using 2.5 mg oral minoxidil, 1 mg finasteride, 5% minoxidil, ketoconazole shampoo, and kLM d3. He plans to post progress pictures every 6 weeks and is seeking suggestions.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

1 mg of finasteride is commonly prescribed because it is more effective for a larger number of people compared to lower doses, despite only slightly reducing serum DHT more than 0.2 mg. Serum DHT and scalp DHT are different, and 1 mg is believed to reduce scalp DHT more effectively, contributing to better hair growth results.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The user has been using 1mg finasteride and 2.5mg oral minoxidil for three months, noticing new blonde hairs but experiencing ongoing shedding. They also use GHK-Cu, which has improved skin but not hair.

A user started taking 2.5mg oral Minoxidil (OM) and 1mg Finasteride after using topical Finasteride, Minoxidil, and Tretinoin for 2.5 months. They are considering increasing the OM dose before an upcoming hair transplant to improve its success.

A 28-year-old male shares progress using 5mg Minoxidil and 0.5mg Dutasteride for hair growth, encouraging the use of these treatments. Users discuss side effects like increased facial hair and debate the effectiveness of treatments within three months.

The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

2.5mg oral minoxidil can be effective for hair regrowth, but 5mg often shows more dramatic results. Users at Norwood 2 using 1mg finasteride may see modest regrowth with 2.5mg, and it's suggested to give it a proper trial.